ArticleEULAR rheumatology open2025
Differential joint-level response to secukinumab in psoriatic arthritis: A collaborative European observational cohort study.
Article in EULAR rheumatology open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate possible variations in treatment response to secukinumab at distinct anatomic joint locations in patients with psoriatic arthritis (PsA) in routine clinical care. Methods: Patients with PsA monitored in 9 registries contributing to the European Spondyloarthritis Research Collaboration Network were included in this study if at least 1 joint from the 28-joint count was clinically swollen at the start of treatment with secukinumab. The primary outcome was time to first resolution of clinical joint swelling at each joint location, excluding the shoulder, during a follow-up of 2 years. Estimated hazard ratios (HRs) for resolution between different joint locations were compared with interval-censored mixed-effects transformation models adjusted for age, sex, and previous biologic/targeted synthetic disease-modifying antirheumatic drug (DMARD). Results: A total of 590 patients with 2794 swollen joints at the initiation of secukinumab were included (mean [SD] age 51.7 [12.3] years, 54% female patients, 77% co-treatment with conventional synthetic DMARDs). Compared with the wrist, the elbow had a higher rate of resolution of joint swelling (HR = 1.75, 95% CI = 1.10-2.79). The metacarpophalangeal joints (MCP) 4 and 5 (HR = 2.01, 95% CI = 1.40-2.88 and HR = 1.98, 95% CI = 1.28-3.06, respectively), as well as most proximal interphalangeal joints (PIP), except PIP3, had a higher rate of resolution compared with the wrist. No significant difference in the resolution of joint swelling was found for the wrist compared with MCP2, MCP3, PIP3, and the knee. Conclusions: In PsA, the time to resolution of joint swelling after initiation of secukinumab differs between distinct joint locations.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.